TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02429414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Video Double Lumen Tube (DLT)
Description: Participant receives non-video double lumen tube (DLT) placement before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiberoptic Bronchoscopy (FOB)
Description: Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Double Lumen Tube (VDLT)
Description: Participant receives video double lumen tube (VDLT) placement before surgery.
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15
Study: NCT00849732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V520
Description: Intentionally Blank
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO BID; Days 1- 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO BID; Days 1- 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO BID; Days 1- 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 4 and 11
Study: NCT00849732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V520 (1x10^9 vp/d)
Description: 1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V520 (1x10^10 vp/d)
Description: 1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 4 and 11
Study: NCT03825770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PEP (Personal Energy Planning) Program
Description: The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts \~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Education about Kidney Disease
Description: General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference).
Study: NCT03167996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of HealthPals (Telemedicine supported by digital health platform)
Description: HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc.
Study: NCT00202735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm1:Immobilization in external rotation
Description: Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immobilization in internal rotation
Description: All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 4 and 11
Study: NCT05826756

Intervention type: OTHER
Intervention: There are no interventions in this study. All participants complete online surveys.
Description: There are no interventions in this study. All participants complete online surveys.

Intervention type: OTHER
Intervention: There are no interventions in this study. All participants complete online surveys.
Description: There are no interventions in this study. All participants complete online surveys.
Study: NCT02173574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEB025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239
Study: NCT03480100

Intervention type: DRUG
Intervention: Xylometazoline Nasal Spray
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use

Intervention type: DRUG
Intervention: Xylometazoline Nasal Spray
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use

Intervention type: DEVICE
Intervention: Ectoin Nasal Douche
Description: Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
Study: NCT03029143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab intravenous infusion.
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 4 and 11
Study: NCT02588976

Intervention type: DEVICE
Group type: OTHER
Intervention: Sonoclot Analyzer
Description: Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
Study: NCT02122003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg bid
Study: NCT00892736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02348333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981, (Oral daily dosing for 7 days)
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Oral daily dosing for 7 days)
Description: Subjects randomized to the placebo arm receive placebo.
Study: NCT00892736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT01462604

Intervention type: OTHER
Intervention: non-drug intervention educational programme
Description: educational programme
Study: NCT02254655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puerarin injection 400 mg
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
Study: NCT02215356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib with concurrent radiotherapy
Description: Icotinib: 125 mg is administered orally three times per day.
Study: NCT04441541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with auditory feedback
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with visual feedback
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill with auditory and visual feedback
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Participants will receive training 3 times per week for 4 weeks (12 sessions).
Study: NCT02856217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling
Description: In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-tunneling
Description: In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
Study: NCT04190888

Intervention type: OTHER
Intervention: No intervention
Description: No intervention - observational study
Study: NCT02014701

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiogram
Description: 1. Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~2. Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software.
Study: NCT04356651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling(FSN)
Description: In this study, physician will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin from anterior superior iliac spine(ASIS) to 1/3 superior border of patella. Then the physician will push forward the needle parallel to the skin surface. The physician will sway the needle 45 times in 30 seconds. After swaying the needle, the physician will instruct the subject to do sole dorsiflexion for 10 seconds resisting the physician's opposite force, then the subject take a rest for 10 seconds. The above actions are 3 repetitions. Then the subject do knee flexion and extension for 10 seconds, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the physician will take out the needle to finish the treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction.
Study: NCT03328208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Talk® app
Description: Test app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Noise app
Description: White Noise app built to mimic appearance of Comfort Talk® test app
Study: NCT00565461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: 37.5ug patch applied on either the deltoid or the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: 37.5ug patch applied on either the deltoid or the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: 37.5ug patch applied on either the deltoid or the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: 37.5ug patch applied on either the deltoid or the thigh
Study: NCT05304325

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants

Intervention type: OTHER
Intervention: Blood pressure
Description: Systolic and diastolic blood pressure will be measured.
Study: NCT02328365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured medical follow-up after operation
Description: Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
Study: NCT04336501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
Study: NCT03208296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
Study: NCT05304325

Intervention type: OTHER
Intervention: Blood pressure
Description: Systolic and diastolic blood pressure will be measured.

Intervention type: OTHER
Intervention: Blood pressure
Description: Systolic and diastolic blood pressure will be measured.
Study: NCT03230370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UFT
Description: The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LFT
Description: The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
Study: NCT02074683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Year A Pathway
Description: Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
Study: NCT05304325

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Body weight, height and waist circumference will be measured.

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Body weight, height and waist circumference will be measured.
Study: NCT02074683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Year B Pathway
Description: Standard of Care Followed by Fat Grafting Operative Procedure
Study: NCT05304325

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Body weight, height and waist circumference will be measured.
Study: NCT02614599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP22042013
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
Study: NCT01980667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: vials containing 1 mg/ml concentrate for solution for infusion
Study: NCT05304325

Intervention type: OTHER
Intervention: Body composition
Description: Body composition will be evaluated by dual-energy X-ray absorptiometry.
Study: NCT00742144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
Study: NCT05304325

Intervention type: OTHER
Intervention: Body composition
Description: Body composition will be evaluated by dual-energy X-ray absorptiometry.

Intervention type: OTHER
Intervention: Body composition
Description: Body composition will be evaluated by dual-energy X-ray absorptiometry.

Intervention type: OTHER
Intervention: Resting metabolic rate
Description: Resting metabolic rate will be measured by indirect calorimetry.

Intervention type: OTHER
Intervention: Resting metabolic rate
Description: Resting metabolic rate will be measured by indirect calorimetry.

Intervention type: OTHER
Intervention: Resting metabolic rate
Description: Resting metabolic rate will be measured by indirect calorimetry.

Intervention type: OTHER
Intervention: Food intake
Description: Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.

Intervention type: OTHER
Intervention: Food intake
Description: Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.